Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19)

被引：80

作者：

Boucau, Julie ^{[1
]}

Uddin, Rockib ^{[2
]}

Marino, Caitlin ^{[1
]}

Regan, James ^{[3
]}

Flynn, James P. ^{[3
]}

Choudhary, Manish C. ^{[3
,4
]}

Chen, Geoffrey ^{[2
]}

Stuckwisch, Ashley M. ^{[2
]}

Mathews, Josh ^{[2
]}

Liew, May Y. ^{[2
]}

Singh, Arshdeep ^{[2
]}

Reynolds, Zahra ^{[2
]}

Iyer, Surabhi L. ^{[2
]}

Chamberlin, Grace C. ^{[2
]}

Vyas, Tammy D. ^{[2
]}

Vyas, Jatin M. ^{[2
,4
]}

Turbett, Sarah E. ^{[2
]}

Li, Jonathan Z. ^{[3
,4
]}

Lemieux, Jacob E. ^{[2
,4
,5
]}

Barczak, Amy K. ^{[1
,2
,4
]}

Siedner, Mark J. ^{[2
,4
]}

机构：

[1] Massachusetts Inst Technol MIT & Harvard, Massachusetts Gen Hosp MGH, Ragon Inst, Cambridge, MA USA

[2] Massachusetts Gen Hosp, Boston, MA 02215 USA

[3] Brigham & Womens Hosp, Boston, MA 02215 USA

[4] Harvard Med Sch, Boston, MA 02215 USA

[5] Broad Inst, Cambridge, MA 02138 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2023年 / 76卷 / 03期

关键词：

COVID-19; therapeutics; anti-virals; nirmatrelvir-ritonavir; virology;

D O I：

10.1093/cid/ciac512

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We enrolled 7 individuals with recurrent symptoms or antigen test conversion following nirmatrelvir-ritonavir treatment. High viral loads (median 6.1 log(10) copies/mL) were detected after rebound for a median of 17 days after initial diagnosis. Three had culturable virus for up to 16 days after initial diagnosis. No known resistance-associated mutations were identified.

引用

页码：E526 / E529

页数：4

共 50 条

[21] Nirmatrelvir-ritonavir treatment of COVID-19 in a high-risk patient population: A retrospective observational study [J].

Kane, Anna M. ;

Keenan, Erica M. ;

Lee, Kasheng ;

Hartkopf, Katherine J. ;

Ludwig, Trisha A. ;

Trapskin, Philip J. ;

Vanderloo, Joshua P. ;

Schulz, Lucas T. .

JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, 2023, 6 (01) :29-33

[22] The Coronavirus Disease 2019 (COVID-19) Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences in Participants Treated With Nirmatrelvir Plus Ritonavir Versus Untreated Controls [J].

Pandit, Jay A. ;

Radin, Jennifer M. ;

Chiang, Danielle C. ;

Spencer, Emily G. ;

Pawelek, Jeff B. ;

Diwan, Mira ;

Roumani, Leila ;

Mina, Michael J. .

CLINICAL INFECTIOUS DISEASES, 2023, 77 (01) :25-31

[23] Effectiveness of nirmatrelvir-ritonavir versus azvudine for adult inpatients with severe or critical COVID-19 [J].

Zhang, Huan ;

Tan, Xiaojiao ;

Chen, Junjun ;

Zhang, Zheng ;

Wang, Chenxi ;

Shi, Haiqing ;

Li, Yao ;

Li, Jianbo ;

Kang, Yan ;

Jin, Xiaodong ;

Liao, Xuelian .

BMJ OPEN RESPIRATORY RESEARCH, 2024, 11 (01)

[24] Effectiveness and safety of nirmatrelvir-ritonavir in kidney transplant recipients with severe kidney dysfunction infected with COVID-19 [J].

Yang, Hui ;

Yu, Xin ;

Hou, Wenjing ;

Liu, Xiangduan ;

Chen, Jiaojiao ;

Zhang, Ying ;

Wang, Ying ;

Zhu, Ying ;

Qian, Qing ;

Ma, Kuifen ;

An, Zhuoling .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2024, 68 (03)

[25] Effectiveness and Safety of Simnotrelvir/Ritonavir and Nirmatrelvir/Ritonavir in the Treatment of Moderate to Severe COVID-19 [J].

Chen, Xin ;

Lin, Xiao-Qing ;

Cheng, Fang ;

Zheng, Shi-Lin ;

Zhang, Qiang ;

Wu, Te ;

Jiang, Xian-Gao ;

Shi, Ji-Chan .

IMMUNITY INFLAMMATION AND DISEASE, 2025, 13 (04)

[26] Nirmatrelvir treatment duration and frequency of COVID-19 rebound [J].

Sudeep, Nathan ;

Kojima, Noah ;

Klausner, Jeffrey D. .

ANTIVIRAL THERAPY, 2025, 30 (01)

[27] Clinical outcomes of nirmatrelvir-ritonavir use in pregnant women during the Omicron wave of the coronavirus disease 2019 pandemic [J].

Lin, Chih-Wei ;

Liang, Yu-Ling ;

Chuang, Ming-Ta ;

Tseng, Chun-Han ;

Tsai, Pei-Yin ;

Su, Mei-Tsz .

JOURNAL OF INFECTION AND PUBLIC HEALTH, 2023, 16 (12) :1942-1946

[28] Effectiveness of nirmatrelvir-ritonavir on severe outcomes of COVID-19 in the era of vaccination and Omicron: An updated meta-analysis [J].

Ombelet, Sien ;

Castanares-Zapatero, Diego ;

Desimpel, Fabian ;

Hulstaert, Frank ;

Stordeur, Sabine ;

Roberfroid, Dominique .

JOURNAL OF MEDICAL VIROLOGY, 2024, 96 (02)

[29] Composite outcome of oral azvudine vs. nirmatrelvir-ritonavir in COVID-19 patients: a retrospective cohort study [J].

Chen, Jingxia ;

Liu, Zhengyue ;

Liu, Ruolin ;

Su, Chengxin ;

Yang, Yunyun ;

Wang, Zhuo .

FRONTIERS IN PHARMACOLOGY, 2025, 16

[30] Real-World Effectiveness of Nirmatrelvir-Ritonavir and Its Acceptability in High-Risk COVID-19 Patients [J].

Kim, Min-Kyung ;

Lee, Kyung-Shin ;

Ham, Sin Young ;

Choi, Youn Young ;

Lee, Eunyoung ;

Lee, Seungjae ;

Lee, Bora ;

Jeon, Jaehyun ;

Chin, Bumsik ;

Kim, Yeonjae ;

Kim, Gayeon ;

Jang, Hee -Chang ;

Choi, Jae-Phil ;

Park, Sang -Won .

JOURNAL OF KOREAN MEDICAL SCIENCE, 2023, 38 (35)

← 1 2 3 4 5 →